Attached files

file filename
EX-99.1 - EX-99.1 - KYTHERA BIOPHARMACEUTICALS INCa13-24312_1ex99d1.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 14, 2013

 


 

KYTHERA BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 


 

Delaware

 

001-35663

 

03-0552903

(State or other jurisdiction
of incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification Number)

 

27200 West Agoura Road,

Calabasas, California 91301

(Address of principal executive offices, including Zip Code)

 

Registrant’s telephone number, including area code: (818) 587-4500

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                          Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                          Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                          Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                          Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 2.02  Results of Operations and Financial Condition.

 

On November 14, 2013, KYTHERA Biopharmaceuticals, Inc. issued a press release relating to its financial results for the quarter ended September 30, 2013.  The full text of the press release is furnished herewith as Exhibit 99.1.

 

The information in this Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01  Financial Statements and Exhibits.

 

The following Exhibit is filed as part of this Current Report on Form 8-K.

 

(d)  Exhibits

 

Exhibit Number

 

Description

 

 

 

99.1

 

KYTHERA Biopharmaceuticals, Inc. Press Release Reporting Third Quarter 2013 Operating Results dated November 14, 2013.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date:

November 14, 2013

 

KYTHERA Biopharmaceuticals, Inc.

 

 

 

 

 

 

 

 

By:

 

 

 

 

 

/s/ Keith R. Leonard, Jr.

 

 

 

 

Keith R. Leonard, Jr.

 

 

 

 

 

 

 

 

 

President and Chief Executive Officer

 

3



 

EXHIBIT INDEX

 

Exhibit Number

 

Description

 

 

 

99.1

 

KYTHERA Biopharmaceuticals, Inc. Press Release Reporting Third Quarter 2013 Operating Results dated November 14, 2013.

 

4